Cancer Research UK & UCL Cancer Trials Centre (H01)![]() The Cancer Research UK and UCL Cancer Trials Centre (CTC) is one of the largest dedicated cancer trials units in the UK. It was formed in 1997, and is now a research department within the UCL Cancer Institute. The CTC develops and conducts high quality studies to find new ways of treating or detecting cancer, and understanding mechanisms of how cancer develops. It has established collaborations with clinicians and scientists, nationally and internationally, to generate new scientific research proposals, develop laboratory projects associated with CTC studies, and train a new generation of clinical trials specialists. Studies are conducted in a wide range of tumours, primarily, lung, lymphoma, gastrointestinal, head and neck, gynaecology, brain, and sarcoma. Cancer Research UK provides the main source of core funding, with additional core support from the Lymphoma Research Trust. Individual projects are funded by competitive grants from Cancer Research UK, the Lymphoma Research Trust, the Medical Research Council, NIHR, and major pharmaceutical companies. FOR ALL QUERIES PLEASE USE THE CONTACT TABS FOUND IN EACH OF THE INDIVIDUAL COURSES/CONFERENCES AND PRODUCTS, PLEASE ONLY CONTACT THE ONLINE STORE DIRECTLY IF YOU ARE EXPERIENCING PAYMENT DIFFICULTIES. Cancer Research UK & UCL Cancer Trials Centre (H01)H01 Running a Trial from Concept to Completion 12/10/2023DescriptionThis session gives an introductory overview of all the steps required to design, set up and complete an academic cancer trial conducted in the hospital setting. Participants will know what all the organisations and people involved in trials do and what permissions and documents need to be in place at different stages of a trial. The course is of most interest to those new to working in academic cancer clinical trials. Those currently working in the field who would like to gain an overview of what happens at other stages to the one familiar to them, may also benefit. This course runs from 10.00 - 13.00
H01 Cancer Treatments and Their Side Effects - Compliance and Adverse Event Reporting 23/10/2023DescriptionThis session is a basic introduction to cancer treatments and their most common side effects and adverse reactions. The course provides an overview on cancer surgery, radiotherapy and chemotherapy we well as insights on the mechanisms of action of targeted therapies such as monoclonal antibodies, small inhibitory molecules, CAR-T cell therapy and immune checkpoint inhibitors. In the second part of the session, participants will learn about the mechanisms of toxicity linked to the different categories of cancer therapy and how these are managed. This course is not recommended for clinicians. Please note that this course runs from 10.00-13.00
H01 Trial Outcomes - What Are We Trying To Measure? 04/12/2023DescriptionThis session, aimed at non-statisticians, will cover the most common primary outcomes measures used in early and late phase cancer trials. Learning Outcomes: Participants will learn what makes a good outcome measure, how outcomes measures are defined and what data need to be collected to assess the outcome, especially for tumour response assessment and time to event measures such as survival and disease (or progression) free survival. Please note that this course runs from 10.00-13.00
H01 RECIST Training 17/10/2023DescriptionThis is a newly developed training session that covers the following aspects:
The course will dedicate ample time to the development of practical skills to learn how to evaluate response according to both RECIST 1.1 and iRECIST via the following activities:
Please note that this course runs from 09.30-13.00
H01 Entering Patients Into Clinical Trials - Pre-Treatment Screening and Eligibility 06/11/2023DescriptionThis session gives a comprehensive overview of the clinical pathways cancer patients can take to be eventually referred for trial entry. The first part of the session spans across the diagnostic methods and staging of cancer and gives a brief overview of the common tests carried out prior to trial treatment. In the second part of the session participants will learn about the importance of ensuring only eligible patients enter a trial and how eligibility criteria help to safeguard patients and differ amongst different phases of trials. They will also learn the importance of assessing treatment compliance and how every clinical intervention comes with a different set of challenges in collecting data about patient compliance. Please note this course runs from 10.00-13.00
H01 Introduction to Cancer Trials for Statisticians November 2023DescriptionThis two-day introductory course is aimed at recent MSc graduates or experienced statisticians new to the field of cancer trials. The course outlines how cancer forms, is diagnosed, staged and treated and links this information to the main outcome measures reported on in cancer clinical trials. By attending this course participants will be better placed to produce cancer clinical trial reports for Data-Monitoring Committees or publications. The faculty of experienced statistical, trial and clinical staff are from three UKCRC Accredited Clinical Trial Units.
|